Wedbush Downgrades Inozyme Pharma (NASDAQ:INZY) to Hold

Inozyme Pharma (NASDAQ:INZY - Get Free Report) was downgraded by stock analysts at Wedbush from a "strong-buy" rating to a "hold" rating in a note issued to investors on Friday,Zacks.com reports. Wedbush also issued estimates for Inozyme Pharma's Q2 2025 earnings at ($0.34) EPS, FY2025 earnings at ($1.23) EPS, Q1 2026 earnings at ($0.25) EPS, Q2 2026 earnings at ($0.26) EPS, Q3 2026 earnings at ($0.26) EPS, Q4 2026 earnings at ($0.24) EPS, FY2026 earnings at ($1.00) EPS and FY2027 earnings at ($0.79) EPS.

A number of other brokerages also recently issued reports on INZY. Jefferies Financial Group reissued a "hold" rating and issued a $4.00 price target (down from $15.00) on shares of Inozyme Pharma in a report on Friday, May 16th. Piper Sandler lowered their target price on shares of Inozyme Pharma from $30.00 to $23.00 and set an "overweight" rating on the stock in a research note on Tuesday, March 11th. Raymond James cut their price target on shares of Inozyme Pharma from $24.00 to $12.00 and set an "outperform" rating for the company in a report on Wednesday, March 12th. Wells Fargo & Company reaffirmed an "equal weight" rating and issued a $4.00 price target on shares of Inozyme Pharma in a report on Friday, May 16th. Finally, Needham & Company LLC downgraded Inozyme Pharma from a "moderate buy" rating to a "hold" rating in a research report on Friday, May 16th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $11.75.

Inozyme Pharma Stock Performance

Shares of NASDAQ INZY traded up $0.01 during midday trading on Friday, hitting $3.96. The company's stock had a trading volume of 1,315,288 shares, compared to its average volume of 808,310. The stock has a fifty day moving average price of $1.27 and a 200 day moving average price of $1.88. The company has a current ratio of 7.68, a quick ratio of 7.68 and a debt-to-equity ratio of 0.51. Inozyme Pharma has a one year low of $0.72 and a one year high of $6.24. The firm has a market capitalization of $255.34 million, a price-to-earnings ratio of -2.54 and a beta of 1.35.

Inozyme Pharma (NASDAQ:INZY - Get Free Report) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.43) by ($0.01). On average, research analysts forecast that Inozyme Pharma will post -1.59 EPS for the current fiscal year.

Institutional Trading of Inozyme Pharma

Institutional investors and hedge funds have recently made changes to their positions in the stock. Affinity Asset Advisors LLC increased its stake in Inozyme Pharma by 40.7% in the fourth quarter. Affinity Asset Advisors LLC now owns 3,972,318 shares of the company's stock valued at $11,003,000 after acquiring an additional 1,150,000 shares during the last quarter. Rock Springs Capital Management LP lifted its stake in Inozyme Pharma by 1.6% during the fourth quarter. Rock Springs Capital Management LP now owns 3,861,983 shares of the company's stock worth $10,698,000 after purchasing an additional 59,100 shares during the last quarter. Millennium Management LLC boosted its holdings in shares of Inozyme Pharma by 7.9% in the 4th quarter. Millennium Management LLC now owns 1,882,274 shares of the company's stock worth $5,214,000 after purchasing an additional 137,821 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Inozyme Pharma by 0.7% during the 4th quarter. Geode Capital Management LLC now owns 1,179,622 shares of the company's stock valued at $3,268,000 after purchasing an additional 8,450 shares during the last quarter. Finally, Knott David M Jr increased its position in shares of Inozyme Pharma by 23.1% during the 4th quarter. Knott David M Jr now owns 695,000 shares of the company's stock valued at $1,925,000 after purchasing an additional 130,451 shares during the last quarter. Hedge funds and other institutional investors own 88.30% of the company's stock.

Inozyme Pharma Company Profile

Inozyme Pharma, Inc, a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis.